Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
NEO412: A temozolomide analog with transdermal activity in melanoma .

Oncotarget

Swenson S, Silva-Hirschberg C, Wang W, Singh A, Hofman FM, Chen KL, Schönthal AH, Chen TC.
PMID: 30651933
Oncotarget. 2018 Dec 11;9(97):37026-37041. doi: 10.18632/oncotarget.26443. eCollection 2018 Dec 11.

Despite new treatments introduced over the past several years, metastatic melanoma remains difficult to cure. Although melanoma

Cite
Swenson S, Silva-Hirschberg C, Wang W, et al. NEO412: A temozolomide analog with transdermal activity in melanoma . Oncotarget. 2018;9(97):37026-37041doi: 10.18632/oncotarget.26443.
Swenson, S., Silva-Hirschberg, C., Wang, W., Singh, A., Hofman, F. M., Chen, K. L., Schönthal, A. H., & Chen, T. C. (2018). NEO412: A temozolomide analog with transdermal activity in melanoma . Oncotarget, 9(97), 37026-37041. https://doi.org/10.18632/oncotarget.26443
Swenson, Steve, et al. "NEO412: A temozolomide analog with transdermal activity in melanoma ." Oncotarget vol. 9,97 (2018): 37026-37041. doi: https://doi.org/10.18632/oncotarget.26443
Swenson S, Silva-Hirschberg C, Wang W, Singh A, Hofman FM, Chen KL, Schönthal AH, Chen TC. NEO412: A temozolomide analog with transdermal activity in melanoma . Oncotarget. 2018 Dec 11;9(97):37026-37041. doi: 10.18632/oncotarget.26443. eCollection 2018 Dec 11. PMID: 30651933; PMCID: PMC6319336.
Copy Download .nbib Format: NLM
Publisher Correction: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis.

Cancer gene therapy

Tang X, Chang C, Hao M, Chen M, Woodley DT, Schönthal AH, Li W.
PMID: 33875808
Cancer Gene Ther. 2021 Sep;28(9):1073. doi: 10.1038/s41417-021-00337-1.

No abstract available.

Cite
Tang X, Chang C, Hao M, et al. Publisher Correction: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis. Cancer Gene Ther. 2021;28(9):1073doi: 10.1038/s41417-021-00337-1.
Tang, X., Chang, C., Hao, M., Chen, M., Woodley, D. T., Schönthal, A. H., & Li, W. (2021). Publisher Correction: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis. Cancer gene therapy, 28(9), 1073. https://doi.org/10.1038/s41417-021-00337-1
Tang, Xin, et al. "Publisher Correction: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis." Cancer gene therapy vol. 28,9 (2021): 1073. doi: https://doi.org/10.1038/s41417-021-00337-1
Tang X, Chang C, Hao M, Chen M, Woodley DT, Schönthal AH, Li W. Publisher Correction: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis. Cancer Gene Ther. 2021 Sep;28(9):1073. doi: 10.1038/s41417-021-00337-1. PMID: 33875808.
Copy Download .nbib Format: NLM
Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia.

Cancers

Schönthal AH, Swenson S, Minea RO, Kim HN, Cho H, Mohseni N, Kim YM, Chen TC.
PMID: 34298603
Cancers (Basel). 2021 Jul 06;13(14). doi: 10.3390/cancers13143385.

Despite progress in the treatment of acute myeloid leukemia (AML), the clinical outcome remains suboptimal and many patients are still dying from this disease. First-line treatment consists of chemotherapy, which typically includes cytarabine (AraC), either alone or in combination...

Cite
Schönthal AH, Swenson S, Minea RO, et al. Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers (Basel). 2021;13(14)doi: 10.3390/cancers13143385.
Schönthal, A. H., Swenson, S., Minea, R. O., Kim, H. N., Cho, H., Mohseni, N., Kim, Y. M., & Chen, T. C. (2021). Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers, 13(14), . https://doi.org/10.3390/cancers13143385
Schönthal, Axel H, et al. "Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia." Cancers vol. 13,14 (2021). doi: https://doi.org/10.3390/cancers13143385
Schönthal AH, Swenson S, Minea RO, Kim HN, Cho H, Mohseni N, Kim YM, Chen TC. Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers (Basel). 2021 Jul 06;13(14). doi: 10.3390/cancers13143385. PMID: 34298603; PMCID: PMC8305595.
Copy Download .nbib Format: NLM
Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor.

BMC molecular biology

Wu RC, Blumenthal M, Li X, Schönthal AH.
PMID: 12113656
BMC Mol Biol. 2002 Jul 12;3:11. doi: 10.1186/1471-2199-3-11. Epub 2002 Jul 12.

BACKGROUND: The tumor suppressor gene PTEN has been found mutated in many types of advanced tumors. When introduced into tumor cells that lack the wild-type allele of the gene, exogenous PTEN was able to suppress their ability to grow...

Cite
Wu RC, Blumenthal M, Li X, et al. Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor. BMC Mol Biol. 2002;3:11doi: 10.1186/1471-2199-3-11.
Wu, R. C., Blumenthal, M., Li, X., & Schönthal, A. H. (2002). Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor. BMC molecular biology, 311. https://doi.org/10.1186/1471-2199-3-11
Wu, Ray-Chang, et al. "Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor." BMC molecular biology vol. 3 (2002): 11. doi: https://doi.org/10.1186/1471-2199-3-11
Wu RC, Blumenthal M, Li X, Schönthal AH. Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor. BMC Mol Biol. 2002 Jul 12;3:11. doi: 10.1186/1471-2199-3-11. Epub 2002 Jul 12. PMID: 12113656; PMCID: PMC117602.
Copy Download .nbib Format: NLM
Endoplasmic reticulum stress: its role in disease and novel prospects for therapy.

Scientifica

Schönthal AH.
PMID: 24278747
Scientifica (Cairo). 2012;2012:857516. doi: 10.6064/2012/857516. Epub 2012 Dec 23.

The endoplasmic reticulum (ER) is a multifunctional organelle required for lipid biosynthesis, calcium storage, and protein folding and processing. A number of physiological and pathological conditions, as well as a variety of pharmacological agents, are able to disturb proper...

Cite
Schönthal AH. Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica (Cairo). 2012;2012:857516doi: 10.6064/2012/857516.
Schönthal, A. H. (2012). Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica, 2012857516. https://doi.org/10.6064/2012/857516
Schönthal, Axel H. "Endoplasmic reticulum stress: its role in disease and novel prospects for therapy." Scientifica vol. 2012 (2012): 857516. doi: https://doi.org/10.6064/2012/857516
Schönthal AH. Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica (Cairo). 2012;2012:857516. doi: 10.6064/2012/857516. Epub 2012 Dec 23. PMID: 24278747; PMCID: PMC3820435.
Copy Download .nbib Format: NLM
Correction to: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis.

Cancer gene therapy

Tang X, Chang C, Hao M, Chen M, Woodley DT, Schönthal AH, Li W.
PMID: 33875807
Cancer Gene Ther. 2021 Sep;28(9):1071-1072. doi: 10.1038/s41417-021-00330-8.

No abstract available.

Cite
Tang X, Chang C, Hao M, et al. Correction to: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis. Cancer Gene Ther. 2021;28(9):1071-1072doi: 10.1038/s41417-021-00330-8.
Tang, X., Chang, C., Hao, M., Chen, M., Woodley, D. T., Schönthal, A. H., & Li, W. (2021). Correction to: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis. Cancer gene therapy, 28(9), 1071-1072. https://doi.org/10.1038/s41417-021-00330-8
Tang, Xin, et al. "Correction to: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis." Cancer gene therapy vol. 28,9 (2021): 1071-1072. doi: https://doi.org/10.1038/s41417-021-00330-8
Tang X, Chang C, Hao M, Chen M, Woodley DT, Schönthal AH, Li W. Correction to: Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis. Cancer Gene Ther. 2021 Sep;28(9):1071-1072. doi: 10.1038/s41417-021-00330-8. PMID: 33875807.
Copy Download .nbib Format: NLM
Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.

Neuro-oncology

Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC.
PMID: 34519783
Neuro Oncol. 2021 Dec 01;23(12):2123. doi: 10.1093/neuonc/noab204.

No abstract available.

Cite
Wang W, He H, Marín-Ramos NI, et al. Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021;23(12):2123doi: 10.1093/neuonc/noab204.
Wang, W., He, H., Marín-Ramos, N. I., Zeng, S., Swenson, S. D., Cho, H. Y., Fu, J., Beringer, P. M., Neman, J., Chen, L., Schönthal, A. H., & Chen, T. C. (2021). Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro-oncology, 23(12), 2123. https://doi.org/10.1093/neuonc/noab204
Wang, Weijun, et al. "Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer." Neuro-oncology vol. 23,12 (2021): 2123. doi: https://doi.org/10.1093/neuonc/noab204
Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC. Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 2021 Dec 01;23(12):2123. doi: 10.1093/neuonc/noab204. PMID: 34519783; PMCID: PMC8643429.
Copy Download .nbib Format: NLM
Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy.

Surgical neurology international

Santos JG, Faria G, Cruz WDCSD, Fontes CA, Schönthal AH, Quirico-Santos T, da Fonseca CO.
PMID: 33282452
Surg Neurol Int. 2020 Nov 11;11:389. doi: 10.25259/SNI_445_2020. eCollection 2020.

BACKGROUND: Standard of care for glioblastoma (GB), consisting of cytotoxic chemotherapy, steroids, and high-dose radiation, induces changes in the tumor microenvironment through its effects on glucose availability, which is a determinant for tumor progression (TP). Low-carbohydrate diet (LCD) reduces...

Cite
Santos JG, Faria G, Cruz WDCSD, et al. Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy. Surg Neurol Int. 2020;11:389doi: 10.25259/SNI_445_2020.
Santos, J. G., Faria, G., Cruz, W. D. C. S. D., Fontes, C. A., Schönthal, A. H., Quirico-Santos, T., & da Fonseca, C. O. (2020). Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy. Surgical neurology international, 11389. https://doi.org/10.25259/SNI_445_2020
Santos, Juliana Guimaraes, et al. "Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy." Surgical neurology international vol. 11 (2020): 389. doi: https://doi.org/10.25259/SNI_445_2020
Santos JG, Faria G, Cruz WDCSD, Fontes CA, Schönthal AH, Quirico-Santos T, da Fonseca CO. Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy. Surg Neurol Int. 2020 Nov 11;11:389. doi: 10.25259/SNI_445_2020. eCollection 2020. PMID: 33282452; PMCID: PMC7710475.
Copy Download .nbib Format: NLM
The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.

Pharmaceutics

Chen TC, da Fonseca CO, Levin D, Schönthal AH.
PMID: 34959448
Pharmaceutics. 2021 Dec 16;13(12). doi: 10.3390/pharmaceutics13122167.

Perillyl alcohol (POH) is a naturally occurring monoterpenoid related to limonene that is present in the essential oils of various plants. It has diverse applications and can be found in household items, including foods, cosmetics, and cleaning supplies. Over...

Cite
Chen TC, da Fonseca CO, Levin D, et al. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics. 2021;13(12)doi: 10.3390/pharmaceutics13122167.
Chen, T. C., da Fonseca, C. O., Levin, D., & Schönthal, A. H. (2021). The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics, 13(12), . https://doi.org/10.3390/pharmaceutics13122167
Chen, Thomas C, et al. "The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers." Pharmaceutics vol. 13,12 (2021). doi: https://doi.org/10.3390/pharmaceutics13122167
Chen TC, da Fonseca CO, Levin D, Schönthal AH. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics. 2021 Dec 16;13(12). doi: 10.3390/pharmaceutics13122167. PMID: 34959448; PMCID: PMC8709132.
Copy Download .nbib Format: NLM
Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice.

Neuro-oncology advances

Cho HY, Swenson S, Thein TZ, Wang W, Wijeratne NR, Marín-Ramos NI, Katz JE, Hofman FM, Schönthal AH, Chen TC.
PMID: 33392507
Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. doi: 10.1093/noajnl/vdaa160. eCollection 2020.

BACKGROUND: NEO212 is a novel small-molecule anticancer agent that was generated by covalent conjugation of the natural monoterpene perillyl alcohol (POH) to the alkylating agent temozolomide (TMZ). It is undergoing preclinical development as a therapeutic for brain-localized malignancies. The...

Cite
Cho HY, Swenson S, Thein TZ, et al. Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice. Neurooncol Adv. 2020;2(1):vdaa160doi: 10.1093/noajnl/vdaa160.
Cho, H. Y., Swenson, S., Thein, T. Z., Wang, W., Wijeratne, N. R., Marín-Ramos, N. I., Katz, J. E., Hofman, F. M., Schönthal, A. H., & Chen, T. C. (2020). Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice. Neuro-oncology advances, 2(1), vdaa160. https://doi.org/10.1093/noajnl/vdaa160
Cho, Hee-Yeon, et al. "Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice." Neuro-oncology advances vol. 2,1 (2020): vdaa160. doi: https://doi.org/10.1093/noajnl/vdaa160
Cho HY, Swenson S, Thein TZ, Wang W, Wijeratne NR, Marín-Ramos NI, Katz JE, Hofman FM, Schönthal AH, Chen TC. Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice. Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. doi: 10.1093/noajnl/vdaa160. eCollection 2020. PMID: 33392507; PMCID: PMC7764505.
Copy Download .nbib Format: NLM
The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.

Pharmaceutics

Chen TC, da Fonseca CO, Levin D, Schönthal AH.
PMID: 34959448
Pharmaceutics. 2021 Dec 16;13(12). doi: 10.3390/pharmaceutics13122167.

Perillyl alcohol (POH) is a naturally occurring monoterpenoid related to limonene that is present in the essential oils of various plants. It has diverse applications and can be found in household items, including foods, cosmetics, and cleaning supplies. Over...

Cite
Chen TC, da Fonseca CO, Levin D, et al. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics. 2021;13(12)doi: 10.3390/pharmaceutics13122167.
Chen, T. C., da Fonseca, C. O., Levin, D., & Schönthal, A. H. (2021). The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics, 13(12), . https://doi.org/10.3390/pharmaceutics13122167
Chen, Thomas C, et al. "The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers." Pharmaceutics vol. 13,12 (2021). doi: https://doi.org/10.3390/pharmaceutics13122167
Chen TC, da Fonseca CO, Levin D, Schönthal AH. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. Pharmaceutics. 2021 Dec 16;13(12). doi: 10.3390/pharmaceutics13122167. PMID: 34959448.
Copy Download .nbib Format: NLM
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma.

Neuro-oncology advances

Schönthal AH, Peereboom DM, Wagle N, Lai R, Mathew AJ, Hurth KM, Simmon VF, Howard SP, Taylor LP, Chow F, da Fonseca CO, Chen TC.
PMID: 33604574
Neurooncol Adv. 2021 Feb 12;3(1):vdab005. doi: 10.1093/noajnl/vdab005. eCollection 2021.

BACKGROUND: Better treatments for glioblastoma (GBM) patients, in particular in the recurrent setting, are urgently needed. Clinical trials performed in Brazil indicated that intranasal delivery of perillyl alcohol (POH) might be effective in this patient group. NEO100, a highly...

Cite
Schönthal AH, Peereboom DM, Wagle N, et al. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv. 2021;3(1):vdab005doi: 10.1093/noajnl/vdab005.
Schönthal, A. H., Peereboom, D. M., Wagle, N., Lai, R., Mathew, A. J., Hurth, K. M., Simmon, V. F., Howard, S. P., Taylor, L. P., Chow, F., da Fonseca, C. O., & Chen, T. C. (2021). Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neuro-oncology advances, 3(1), vdab005. https://doi.org/10.1093/noajnl/vdab005
Schönthal, Axel H, et al. "Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma." Neuro-oncology advances vol. 3,1 (2021): vdab005. doi: https://doi.org/10.1093/noajnl/vdab005
Schönthal AH, Peereboom DM, Wagle N, Lai R, Mathew AJ, Hurth KM, Simmon VF, Howard SP, Taylor LP, Chow F, da Fonseca CO, Chen TC. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv. 2021 Feb 12;3(1):vdab005. doi: 10.1093/noajnl/vdab005. eCollection 2021. PMID: 33604574; PMCID: PMC7879254.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries